State Street
MRVI icon

State Street’s Maravai LifeSciences MRVI Stock Holding History

State Street’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.1M Buy
2,901,706
+472,989
+19% +$2.04M ﹤0.01% 2410
2026
Q1 		$6.87M Buy
2,428,717
+14,468
+0.6% +$49.1K ﹤0.01% 2803
2025
Q4 		$7.85M Buy
2,414,249
+27,219
+1% +$91.6K ﹤0.01% 2770
2025
Q3 		$6.85M Buy
2,387,030
+5,719
+0.2% +$14.6K ﹤0.01% 2848
2025
Q2 		$5.74M Sell
2,381,311
-345,443
-13% -$726K ﹤0.01% 2885
2025
Q1 		$6.03M Sell
2,726,754
-54,043
-2% -$214K ﹤0.01% 2805
2024
Q4 		$15.2M Buy
2,780,797
+30,024
+1% +$193K ﹤0.01% 2377
2024
Q3 		$22.9M Sell
2,750,773
-16,338
-0.6% -$141K ﹤0.01% 2129
2024
Q2 		$19.8M Buy
2,767,111
+730,837
+36% +$6.31M ﹤0.01% 2177
2024
Q1 		$17.7M Buy
2,036,274
+20,906
+1% +$141K ﹤0.01% 2248
2023
Q4 		$13.2M Buy
2,015,368
+207,869
+12% +$1.34M ﹤0.01% 2437
2023
Q3 		$18.1M Sell
1,807,499
-26,994
-1% -$296K ﹤0.01% 2227
2023
Q2 		$22.8M Sell
1,834,493
-5,975
-0.3% -$80.6K ﹤0.01% 2168
2023
Q1 		$25.8M Buy
1,840,468
+32,279
+2% +$464K ﹤0.01% 2052
2022
Q4 		$25.9M Buy
1,808,189
+53,213
+3% +$838K ﹤0.01% 2050
2022
Q3 		$44.8M Buy
1,754,976
+6,088
+0.3% +$153K ﹤0.01% 1663
2022
Q2 		$49.7M Sell
1,748,888
-61,429
-3% -$1.95M ﹤0.01% 1638
2022
Q1 		$63.9M Buy
1,810,317
+201,284
+13% +$6.75M ﹤0.01% 1604
2021
Q4 		$67.4M Buy
1,609,033
+222,158
+16% +$9M ﹤0.01% 1599
2021
Q3 		$68.1M Buy
1,386,875
+166,491
+14% +$8.12M ﹤0.01% 1578
2021
Q2 		$50.9M Buy
1,220,384
+571,855
+88% +$22.2M ﹤0.01% 1834
2021
Q1 		$23.1M Buy
+648,529
New +$21.5M ﹤0.01% 2277

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.91B AUM 14.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OAM
Ophir Asset Management Sydney, Australia $1.22B AUM 100.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

State Street's MRVI Position: Q2 2026 in Review

State Street increased its Maravai LifeSciences (MRVI) stake by 19% in Q2 2026, buying an estimated $2.04M and bringing the position to 2,901,706 shares worth $18.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2410.

State Street first reported a position in MRVI in Q1 2021 and has held it in 22 quarters since. The position peaked at $68.1M in Q3 2021. 178 funds tracked by Wall St. Rank hold MRVI as of Q2 2026.

  • State Street held 2,901,706 shares of Maravai LifeSciences worth $18.1M as of Q2 2026.
  • State Street bought 472,989 Maravai LifeSciences shares in Q2 2026, an estimated $2.04M.
  • Maravai LifeSciences made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2410 holding.
  • State Street first reported a position in Maravai LifeSciences in Q1 2021 and has held it in 22 quarters since.
  • State Street's Maravai LifeSciences position peaked at $68.1M in Q3 2021.
  • 178 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.